EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ

European Urology

Volumn 48, Issue 3, 2005, Pages 363-371

  Van Der Meijden, Adrian P M ^a   Sylvester, Richard ^b   Oosterlinck, Willem ^c   Solsona, Eduardo ^d   Boehle, Andreas ^e   Lobel, Bernard ^f   Rintala, Erkki ^g  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e HELIOS AGNES KARLL HOSPITAL   (Germany)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bacillus Calmette Guerin; Bladder cancer; Carcinoma in situ; Chemotherapy; Diagnosis; Follow up; Treatment

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BROPIRIMINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; THIOTEPA; VALRUBICIN;

BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOMA IN SITU; CLINICAL PRACTICE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYSTECTOMY; CYSTITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 23944478860     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.05.011     Document Type: Article

References (69)

1. D.L. Lamm Carcinoma in situ Urol Clin N Am 19 1992 499 508
2. M.A. Hudson, and H.W. Herr Carcinoma in situ of the bladder J Urol 153 1995 564 572
3. K.H. Kurth, P.F. Schellhammer, E. Okajima, A. Akdas, G. Jakse, and H.W. Herr Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra Int J Urol 2 Suppl 2 1995 8 22
4. D.L. Lamm, A.P.M. van der Meijden, H. Akaza, C.B. Brendler, P.O. Hedlund, and Y. Mizutani Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 2 Suppl 2 1995 23 25
5. D.L. Lamm, H.W. Herr, G. Jakse, M. Kuroda, F.K. Mostofi, and E. Okajima Updated concepts and treatment of carcinoma in situ Urol Oncol 4 1998 130 138
6. G. Jakse Carcinoma in situ R.R. Hall Clinical management of bladder cancer 1999 Arnold London 149 170
7. J.C. Kim, and G.D. Steinberg The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder J Urol 165 2001 745 756
8. J.A. Witjes Bladder carcinoma in situ in 2003: state of the art Eur Urol 45 2004 142 146
9. Sylvester R, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, et al. High grade Ta urothelial carcinoma and carcinoma in situ of the bladder. WHO/ICUD/SIU Consultation on Bladder Cancer, Honolulu, Hawaii, October 3-7, 2004.
10. Sylvester RJ, van der Meijden APM, Witjes JA, Kurth KH. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-92.
11. E. Kaasinen, H. Wijkstrom, P.U. Malmstrom, S. Hellsten, M. Duchek, and O. Mestad Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study Eur Urol 43 2003 637 645
12. J. Palou, J. Salvador, R. Parada, G. Chechile, F. Millan, and J. Vicente Carcinoma in situ of the prostatic urethra: the role of intravesical BCG Urol Integr Invest 6 2001 165 170
13. Sobin LH, Wittekind C, editors. Union Internationale Contre le Cancer. TNM Classification of malignant tumors, 6th edition. New York: Wiley-Liss; 2002.
14. J.I. Epstein, M.B. Amin, V.R. Reuter, F.K. Mostofi the Bladder Consensus Conference Committee The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder Am J Surg Path 22 1998 1435 1448
15. D. Zaak, E. Hungerhuber, P. Schneede, H. Stepp, D. Frimberger, and S. Corvin Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions Cancer 95 2002 1234 1238
16. J. Schmidbauer, F. Witjes, N. Schmeller, R. Donat, M. Susani, and M. Marberger Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy J Urol 171 2004 135 138
17. M.A. D'Hallewin, L. Bezdetnaya, and F. Guillemin Fluorescence detection of bladder cancer: a review Eur Urol 42 2002 417 425
18. F.E. Sharkey, and M.F. Sarosdy The significance of central pathology review in clinical studies of transitional cell carcinoma in situ J Urol 157 1997 68 70
19. A.S. Glas, D. Roos, M. Deutekom, A.H. Zwinderman, P.M.M. Bossuyt, and K.H. Kurth Tumor markers in the diagnosis of primary bladder cancer. A systematic review J Urol 169 2003 1975 1982
20. Y. Lotan, and C.G. Roehrborn Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analysis Urology 61 2003 109 118
21. Lokeshwar VB, Bono AV, Schmitz-Drager B, Droller MJ, Fradet Y, Goebell P, et al. Tumor markers beyond cytology. WHO/ICUD/SIU Consultation on Bladder Cancer, Honolulu, Hawaii, October 3-7, 2004.
22. E. Solsona, I. Iborra, J.V. Ricos, R. Dumont, J.L. Casanova, and C. Calabuig Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management Urology 49 1997 347 352
23. A. Lopez-Beltran, P.F. Bassi, M. Pavone-Macaluso, and R. Montironi Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis Eur Urol 45 2004 257 266
24. A. Losa, R. Hurle, and A. Lembo Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results J Urol 163 2000 68 72
25. G. Jakse members of the EORTC GU Group Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861 Eur Urol 40 2001 144 150
26. T.M. De Reijke, K.H. Kurth, R.J. Sylvester, R.R. Hall, M. Brausi, and K. van de Beek Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer Genito-Urinary Group phase III trial (30906) J Urol 173 2005 405 409
27. V.W. Merz, D. Marth, R. Kraft, D.K. Ackermann, E.J. Zingg, and U.E. Studer Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guerin for carcinoma in situ of the bladder Br J Urol 75 1995 180 184
28. D.E. Coplen, M.D. Marcus, J.A. Myers, T.L. Ratliff, and W.J. Catalona Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free tumor J Urol 144 1990 652 657
29. D.L. Lamm, B.A. Blumenstein, J.D. Crissman, J.E. Montie, J.E. Gottesman, and B.A. Lowe Maintenance BCG immunotherapy for recurrent Ta, T1 and CIS transitional cell carcinoma of the bladder: a randomized SWOG study J Urol 163 2000 1124 1129
30. G. Jakse BCG for carcinoma in situ Eur Urol 21 suppl 2 1992 30 34
31. P.U. Malmstrom, H. Wijkstrom, C. Lundholm, K. Wester, C. Busch, and B.J. Norlen 5 year follow up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder cancer J Urol 161 1999 1124 1127
32. D.L. Lamm, B.A. Blumenstein, E.D. Crawford, J.D. Crissman, B.A. Lowe, and J.A. Smith Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Southwest Oncology Group Study Urol Oncol 1 1995 119 126
33. J.A. Witjes, A.P.M. van der Meijden, L. Collette, R. Sylvester, F.M.J. Debruyne, and A. van Aubel Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and Mitomycin C in superficial bladder cancer Urology 52 1998 403 410
34. P.D. Vegt, J.A. Witjes, W.P. Witjes, W.H. Doesburg, F.M. Debruyne, and A.P. van der Meijden A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder J Urol 153 1995 929 933
35. S.M. Di Stasi, A. Giannantoni, R.L. Stephen, G. Capelli, P. Navarra, and R. Massoud Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777 782
36. D.L. Lamm, B.A. Blumenstein, E.D. Crawford, J.E. Montie, P. Scardino, and H.B. Grossman A randomized trial of intravesical doxorubicin and immunotherapy with BCG for transitional cell carcinoma of the bladder N Engl J Med 325 1991 1205 1209
37. J.A. Martinez-Pineiro, J. Jimenez Leon, L. Martinez-Pineiro, L. Fiter, J.A. Mosteiro, and J. Navarro Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer J Urol 143 1990 502 506
38. M.D. Melekos, H.S. Chionis, G.S. Paranychianakis, and H.H. Dauaher Intravesical 4′-epi-doxorubin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer Cancer 72 1993 1749 1755
39. H. Sekine, K. Ohya, S.I. Kojima, K. Igarashi, and I. Fukui Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder Int J Urol 8 2001 483 486
40. E. Rintala the Finnbladder Group Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder J Urol 154 1995 2050 2053
41. J.A. Witjes, C.T.M. Caris, N.A. Mungan, F.M.J. Debruyne, and W.P.J. Witjes Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer J Urol 160 1998 1668 1672
42. R.J. Sylvester, A.P.M. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
43. H.W. Herr, and W.F. Whitmore Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management J Urol 138 1987 292 294
44. N. Nonomura, Y. Ono, M. Nozawa, T. Fukui, Y. Harada, and K. Nishimura Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract Eur Urol 38 2000 701 705
45. G.N. Thalmann, R. Markwalder, B. Walter, and U.E. Studer Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery J Urol 168 2002 1381 1385
46. D.L. Lamm, APM van der Meijden, A. Morales, S.A. Brosman, W.J. Catalona, and H.W. Herr Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer J Urol 147 1992 596 600
47. A.P.M. van der Meijden, M. Brausi, V. Zambon, W. Kirkels, C. de Balincourt, and R. Sylvester Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial J Urol 166 2001 476 481
48. A.P.M. van der Meijden, R.J. Sylvester, W. Oosterlinck, W. Hoeltl, and A.V. Bono Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group phase III trial Eur Urol 44 2003 429 434
49. A. Bohle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95
50. F. Saint, J. Irani, J.J. Patard, L. Salmon, A. Hoznek, and S. Zammattio Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer Urology 57 2001 883 888
51. G. Morgia, M. Falsaperla, M. Madonia, F. Vacirca, G. La Pira, and G. De Grande Use of BCG in immunotherapy of superficial bladder cancer: multicentric investigation on safety and compliance Uro Oncol 2 2002 129 135
52. G. Steinberg, R. Bahnson, S. Brosman, R. Middleton, Z. Wajsman, and M. Wehle Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder J Urol 163 2000 761 767
53. S.V. Onrust, and H.M. Lamb Valrubicin Drugs Aging 15 1999 69 75
54. R.E. Greenberg, R.R. Bahnson, D. Wood, S.J. Childs, C. Bellingham, and M. Edson Initial report on intravesical administration of N- trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder Urology 49 1997 471 475
55. R.W. Glashan A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder J Urol 144 1990 658 661
56. F.M. Torti, L.D. Shortliffe, R.D. Williams, W.C. Pitts, R.L. Kempson, and J.C. Ross Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study J Clin Oncol 6 1988 476 483
57. R.D. Williams, D.M. Gleason, A.Y. Smith, N.R. Zinner, A.I. Sagalowsky, and J.E. Montie Pilot study of intravesical alpha-2b interferon for treatment of bladder carcinoma in situ following BCG failure J Urol 155 Suppl 1996 494A [Abstract 735]
58. M.A. O'Donnell the National Bacillus Calmette-Guerin/Interferon phase 2 Investigator Group Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2b for superficial bladder cancer J Urol 172 2004 888 893
59. M.F. Sarosdy, M.J. Manyak, A.I. Sagalowsky, A. Belldegrun, M.C. Benson, and W. Bihrle Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin Urology 51 1998 226 231
60. M.F. Sarosdy A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract Eur Urol 31 Suppl 1 1997 20 26
61. M.F. Sarosdy, L.L. Pisters, P.R. Carroll, M.C. Benson, T.D. Moon, and D.L. Lamm Bropirimine immunotherapy of upper urinary tract carcinoma in situ Urology 48 1996 28 32
62. M.F. Sarosdy, B.A. Lowe, P.F. Schellhammer, D.L. Lamm, S.D. Graham Jr., and H.B. Grossman Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial Urology 48 1996 21 27
63. A.P. Berger, H. Steiner, A. Stenzl, T. Akkad, G. Bartsch, and L. Holtl Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study Urology 61 2003 338 341
64. M.J. Manyak, and K. Ogan Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium J Endourol 17 2003 633 639
65. U.O. Nseyo, B. Shumaker, E.A. Klein, and K. Sutherland Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group J Urol 160 1998 39 44
66. U.O. Nseyo, J. DeHaven, T.J. Dougherty, W.R. Potter, D.L. Merrill, and S.L. Lundahl Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience J Clin Laser Med Surg 16 1998 61 68
67. W. Oosterlinck The EAU Working Group on Oncological Urology Guidelines on bladder cancer Eur Urol 41 2002 105 112
68. F.N. Joudi, and M.A. O'Donnell Second-line intravesical therapy versus cystectomy for bacilli Calmette-Guerin (BCG) failures Cur Opin Urol 14 2004 271 275
69. G. Dalbagni, P. Russo, J. Sheinfeld, M. Mazumdar, W. Tong, and F. Rabbani Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin refractory transitional cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198